Detection of cell-free circulating BRAF
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
accepted:
15
05
2019
pubmed:
19
5
2019
medline:
11
5
2021
entrez:
19
5
2019
Statut:
ppublish
Résumé
The p.V600E mutation in the BRAF protein is the most frequent mutation in cutaneous melanoma and is a recurrent alteration found in common benign naevi. Analysis of the cell-free BRAF c.1799T>A, p.V600E mutation (cfBRAF To quantify cfBRAF We quantified cfBRAF Among disease-free patients and individuals without melanoma, 52% presented a high naevus count (> 50) and 49% had clinically atypical naevi. cfBRAF This study suggests that naevus-related factors do not influence the detection of cfBRAF
Sections du résumé
BACKGROUND
The p.V600E mutation in the BRAF protein is the most frequent mutation in cutaneous melanoma and is a recurrent alteration found in common benign naevi. Analysis of the cell-free BRAF c.1799T>A, p.V600E mutation (cfBRAF
OBJECTIVES
To quantify cfBRAF
METHODS
We quantified cfBRAF
RESULTS
Among disease-free patients and individuals without melanoma, 52% presented a high naevus count (> 50) and 49% had clinically atypical naevi. cfBRAF
CONCLUSIONS
This study suggests that naevus-related factors do not influence the detection of cfBRAF
Substances chimiques
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
382-389Subventions
Organisme : CERCA Programme, Generalitat de Catalunya, Spain.
Pays : International
Organisme : CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain
Pays : International
Organisme : Fundació la Marató de TV3
ID : 201331-30
Pays : International
Organisme : Seventh Framework Programme
Pays : International
Organisme : Ministerio de Educación, Cultura y Deportes, Spain.
ID : FPU17/05453
Pays : International
Organisme : Fondo de Investigaciones Sanitarias, Spain
ID : PI15/00716
Pays : International
Organisme : Fondo de Investigaciones Sanitarias, Spain
ID : PI15/00956
Pays : International
Organisme : Agència de Gestió d'Ajuts Universitaris i de Recerca
ID : 2017_SGR_1134
Pays : International
Informations de copyright
© 2019 British Association of Dermatologists.
Références
Siravegna G, Marsoni S, Siena S et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 2017; 14:531-48.
Jahr S, Hentze H, Englisch S et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61:1659-65.
Wan JCM, Massie C, Garcia-Corbacho J et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 2017; 17:223-38.
Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker - a critical appraisal of the literature. Clin Chim Acta 2010; 411:1611-24.
Gormally E, Caboux E, Vineis P et al. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 2007; 635:105-17.
El Messaoudi S, Rolet F, Mouliere F et al. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta 2013; 424:222-30.
Markus H, Contente-Cuomo T, Farooq M et al. Evaluation of pre-analytical factors affecting plasma DNA analysis. Sci Rep 2018; 8:7375.
Devonshire AS, Whale AS, Gutteridge A et al. Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem 2014; 406:6499-512.
Daniotti M, Vallacchi V, Rivoltini L et al. Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int J Cancer 2007; 120:2439-44.
Pinzani P, Salvianti F, Cascella R et al. Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients. Clin Chim Acta 2010; 411:1319-24.
Busser B, Lupo J, Sancey L et al. Plasma circulating tumor DNA levels for the monitoring of melanoma patients: landscape of available technologies and clinical applications. Biomed Res Int 2017; 2017:5986129.
Nikolaou V, Stratigos AJ. Emerging trends in the epidemiology of melanoma. Br J Dermatol 2014; 170:11-19.
Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-54.
Heinzerling L, Baiter M, Kuhnapfel S et al. Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations. Br J Cancer 2013; 109:2833-41.
Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16.
Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380:358-65.
Melis C, Rogiers A, Bechter O et al. Molecular genetic and immunotherapeutic targets in metastatic melanoma. Virchows Arch 2017; 471:281-93.
Calapre L, Warburton L, Millward M et al. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Lett 2017; 404:62-9.
Ichii-Nakato N, Takata M, Takayanagi S et al. High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi. J Invest Dermatol 2006; 126:2111-18.
Gandini S, Sera F, Cattaruzza MS et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005; 41:28-44.
Huang JM, Chikeka I, Hornyak TJ. Melanocytic nevi and the genetic and epigenetic control of oncogene-induced senescence. Dermatol Clin 2017; 35:85-93.
Ribero S, Davies JR, Requena C et al. High nevus counts confer a favorable prognosis in melanoma patients. Int J Cancer 2015; 137:1691-8.
Bataille V, Kato BS, Falchi M et al. Nevus size and number are associated with telomere length and represent potential markers of a decreased senescence in vivo. Cancer Epidemiol Biomarkers Prev 2007; 16:1499-502.
Pinzani P, Salvianti F, Orlando C et al. Circulating cell-free DNA in cancer. Methods Mol Biol 2014; 1160:133-45.
Gray ES, Rizos H, Reid AL et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget 2015; 6:42008-18.
Lee RJ, Gremel G, Marshall A et al. Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma. Ann Oncol 2018; 29:490-6.
Chang GA, Tadepalli JS, Shao Y et al. Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression. Mol Oncol 2016; 10:157-65.
Sanmamed MF, Fernandez-Landazuri S, Rodriguez C et al. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem 2015; 61:297-304.
McEvoy AC, Pereira MR, Reid A et al. Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. Oncotarget 2019; 10:113-22.
Salvianti F, Pinzani P, Verderio P et al. Multiparametric analysis of cell-free DNA in melanoma patients. PLOS ONE 2012; 7:e49843.
Salerni G, Carrera C, Lovatto L et al. Benefits of total body photography and digital dermatoscopy (‘two-step method of digital follow-up’) in the early diagnosis of melanoma in patients at high risk for melanoma. J Am Acad Dermatol 2012; 67:e17-27.
Puig S, Malvehy J. Monitoring patients with multiple nevi. Dermatol Clin 2013; 31:565-77.
Pakneshan S, Salajegheh A, Smith RA et al. Clinicopathological relevance of BRAF mutations in human cancer. Pathology 2013; 45:346-56.
Puig-Butille JA, Badenas C, Ogbah Z et al. Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma. Exp Dermatol 2013; 22:148-50.
Shain AH, Yeh I, Kovalyshyn I et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med 2015; 373:1926-36.
Huang FW, Hodis E, Xu MJ et al. Highly recurrent TERT promoter mutations in human melanoma. Science 2013; 339:957-9.
McEvoy AC, Calapre L, Pereira MR et al. Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget 2017; 8:78890-900.
Olmedillas-Lopez S, Garcia-Arranz M, Garcia-Olmo D. Current and emerging applications of droplet digital PCR in oncology. Mol Diagn Ther 2017; 21:493-510.
Postel M, Roosen A, Laurent-Puig P et al. Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective. Expert Rev Mol Diagn 2018; 18:7-17.
Hindson BJ, Ness KD, Masquelier DA et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 2011; 83:8604-10.